In the phase II CITYSCAPE study,429 tiragolumab plus atezolizumab as a first-line treatment for PD-L1-positive NSCLC have shown significantly improved efficacy compared with atezolizumab alone. Here, CD274 is linked to non-small cell lung carcinoma.